Poor
Needs Revision
Patient Risk:
Moderate
Summary
The response accurately identifies semaglutide as a GLP-1 receptor agonist and correctly describes label-listed pancreatitis symptoms, including pain that may radiate to the back. However, most claims about remote prior pancreatitis, recurrence risk, alcohol, triglycerides, gallstones, causative medications or toxins, clinician caution, and alternative treatment decisions are not supported by the supplied label sections.
Category Scores
Accurate Statements
Wegovy (semaglutide) is a GLP-1 receptor agonist.
Section 12.1 states that semaglutide acts as a GLP-1 receptor agonist.
Severe, persistent upper abdominal pain with or without vomiting may indicate pancreatitis in a person taking Wegovy.
Section 5.2 identifies persistent or severe abdominal pain, with or without nausea or vomiting, as a possible sign or symptom of acute pancreatitis.
Pancreatitis-related abdominal pain may radiate to the back.
Section 5.2 states that the abdominal pain may sometimes radiate to the back.
Unsupported Statements
GLP-1 medicines carry a warning about the risk of pancreatitis.
The supplied label states that acute pancreatitis has been observed with GLP-1 receptor agonists, including Wegovy, but does not establish that all GLP-1 medicines carry the same warning.
A history of pancreatitis is an important safety factor when deciding whether to use a GLP-1 drug.
The supplied sections do not discuss prior pancreatitis as a treatment-selection factor.
For pancreatitis that occurred decades ago and has fully resolved, the decision to use Wegovy is often individualized.
The supplied label does not address remote or resolved pancreatitis or individualized treatment decisions.
The cause of prior pancreatitis is considered when deciding whether to use Wegovy.
The supplied label does not identify the cause of prior pancreatitis as a prescribing factor.
Whether a person has had additional pancreatitis episodes is considered when deciding whether to use Wegovy.
The supplied label does not address recurrent prior episodes as a treatment-selection factor.
Ongoing alcohol use, gallstones, high triglycerides, and certain medications are current factors considered when assessing pancreatitis risk.
The supplied label does not identify alcohol use, hypertriglyceridemia, or specific medications as pancreatitis-risk assessment factors. It discusses cholelithiasis and cholecystitis separately.
Many prescribers are more cautious about using Wegovy in people with a prior history of pancreatitis, even when the event was remote.
The supplied label does not describe prescriber practice or caution regarding remote prior pancreatitis.
A prescriber may prefer an alternative weight-loss treatment if they consider the risk of recurrent pancreatitis to be higher.
The supplied label does not recommend selecting an alternative weight-loss treatment based on an assessment of recurrent pancreatitis risk.
Clinicians may be especially cautious about Wegovy when prior pancreatitis was associated with active alcohol use.
The supplied label does not address alcohol-associated pancreatitis or special prescribing caution in that setting.
Clinicians may be especially cautious about Wegovy when prior pancreatitis was associated with persistently high triglycerides.
The supplied label does not discuss hypertriglyceridemia as a factor in Wegovy prescribing.
Clinicians may be especially cautious about Wegovy when prior pancreatitis was associated with untreated gallbladder disease or when gallstones have not been evaluated.
Section 5.3 recommends gallbladder studies when cholelithiasis is suspected, but does not state that these prior-history circumstances require special caution regarding Wegovy.
Clinicians may be especially cautious about Wegovy when there is ongoing exposure to the medication or toxin that caused the pancreatitis.
The supplied label does not address causative medications, toxins, or ongoing exposure as prescribing factors.
If the cause of pancreatitis has been corrected, such as by gallbladder removal, triglyceride control, or alcohol avoidance, the risk may be lower.
The supplied label does not discuss correction of pancreatitis causes or whether correction changes pancreatitis risk with Wegovy.
A prior history of pancreatitis generally still requires careful review even when the cause has been corrected.
The supplied label does not address prior pancreatitis history, correction of its cause, or a requirement for careful review.
Contradictions
Important Omissions
The response does not state the label instruction to discontinue Wegovy if pancreatitis is suspected and initiate appropriate management.
Importance:
High
The response does not state that patients should be observed carefully after Wegovy initiation for signs and symptoms of acute pancreatitis.
Importance:
Moderate
The response discusses gallstones and gallbladder disease but omits that Wegovy is associated with increased occurrence of cholelithiasis and cholecystitis and that gallbladder studies and appropriate follow-up are indicated when cholelithiasis is suspected.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly conveys key pancreatitis symptoms but adds numerous unsupported treatment-selection and risk-stratification claims. It also omits the label-directed action to discontinue Wegovy when pancreatitis is suspected, which is material to safe label-consistent communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Most of the response extrapolates beyond the supplied label by presenting prior pancreatitis characteristics and common pancreatitis risk factors as Wegovy prescribing criteria.
Suggested Improvement
Limit the discussion to the supplied label: acute pancreatitis has been observed with Wegovy and other GLP-1 receptor agonists; monitor for persistent or severe abdominal pain, possibly radiating to the back, with or without nausea or vomiting; and discontinue Wegovy and initiate appropriate management if pancreatitis is suspected. Avoid asserting label support for remote prior pancreatitis, recurrence-risk assessment, alcohol, triglycerides, causative medications, or individualized alternative-treatment decisions.